NPS Pharmaceuticals to Present at Upcoming Conferences
BIO CEO & Investor Conference 2013 Leerink Swann Global Healthcare Conference
BEDMINSTER, N.J. -- February 5, 2013
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the 15^th
Annual Bio CEO & Investor Conference in New York on Monday, February 11, 2013
at 10:30 a.m. ET and the Leerink Swann Global Healthcare Conference on
Thursday, February 14, 2013 at 8:00 AM ET. Presentations will be available as
live webcasts with replays available approximately three hours after the
presentations have concluded. Interested parties may access the webcast from
the investors’ calendar of events page on the NPS website at
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan
products to patients with rare disorders and few, if any, therapeutic options.
The company’s lead product, Gattex^® 0.05 mg/kg/d (Teduglutide [rDNA origin])
for Injection is FDA-approved for the treatment of adult patients with short
bowel syndrome (SBS) who are dependent on parenteral support. NPS is also
developing Natpara^® (rhPTH[1-84]) for the treatment of adult
hypoparathyroidism and expects to submit its Biologic License Application
(BLA) to the FDA in mid-2013. NPS's earlier stage pipeline includes two
calcilytic compounds, NPSP790 and NPSP795, with potential application in rare
disorders involving increased calcium receptor activity, such as autosomal
dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its
proprietary programs with a royalty-based portfolio of products and product
candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen
Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH.
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Press spacebar to pause and continue. Press esc to stop.